Modifying risk for aneuploidy with second-trimester ultrasound after a positive serum screen

Clinics in Laboratory Medicine
Diane Timms, Winston A Campbell

Abstract

Prenatal diagnosis for aneuploidy (primarily Down syndrome) has evolved over the past 4 decades. It started as a screening process using maternal age of 35 years or older as a risk factor to offer patients the option for prenatal diagnosis. The actual diagnosis used an invasive procedure (amniocentesis) to obtain fetal cells for processing to determine fetal karyotype. This had a potential risk for miscarriage. The development of noninvasive prenatal screening to better identify pregnant patients at high risk for Down syndrome improved the ability to detect cases of aneuploidy and limit amniocentesis to only patients considered at high risk. This approach has a higher detection rate and a lower procedure-related rate of fetal loss than use of maternal age of 35 years or older alone. This article presents an overview of how prenatal diagnosis has evolved and then focuses on the current status of using ultrasound to evaluate patients considered to be screen-positive for Down syndrome based on first-trimester screening (10-14 weeks) or second-trimester (15-22 weeks) maternal serum analyte screening.

References

Sep 27, 1976·JAMA : the Journal of the American Medical Association
Sep 11, 1992·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·B R BenacerrafF D Frigoletto
Feb 11, 1991·Obstetrics and Gynecology·B R BenacerrafF D Frigoletto
Apr 1, 1988·British Journal of Obstetrics and Gynaecology·N J WaldG E Palomaki
Sep 1, 1985·American Journal of Obstetrics and Gynecology·B R BenacerrafL A Laboda
Nov 26, 1987·The New England Journal of Medicine·B R BenacerrafF D Frigoletto
Apr 1, 1988·British Journal of Obstetrics and Gynaecology·J A CanickN J Wald
Apr 15, 1985·American Journal of Obstetrics and Gynecology·B R BenacerrafL A Laboda
Apr 1, 1984·American Journal of Obstetrics and Gynecology·I R MerkatzW E Johnson
Dec 1, 1995·Obstetrics and Gynecology·B BromleyB R Benacerraf
Mar 1, 1995·American Journal of Obstetrics and Gynecology·A M Vintzileos, J F Egan
Jan 1, 1993·Obstetrics and Gynecology·L LettieriA Craffey
Dec 30, 1996·Early Human Development·H Cuckle
Aug 11, 1998·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·D A NybergM A Williams
May 26, 1999·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·K SpencerK H Nicolaides
Jun 12, 1999·Fetal Diagnosis and Therapy·M Respondek-LiberskaB Danuta
Apr 25, 2000·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·D PaladiniP Martinelli
Jun 10, 2000·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·W H PersutteJ C Hobbins
Mar 7, 2001·JAMA : the Journal of the American Medical Association·R Smith-BindmanJ D Goldberg
Mar 6, 2002·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·U ChitkaraM L Druzin
Jan 16, 2003·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·S CiceroK H Nicolaides
Jul 15, 2003·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·A TuxenI Kjaer
Oct 10, 2003·The New England Journal of Medicine·Ronald WapnerUNKNOWN First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group
Jun 22, 2005·Prenatal Diagnosis·E VioraM Campogrande
Nov 12, 2005·The New England Journal of Medicine·Fergal D MaloneUNKNOWN First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium
Mar 15, 2006·Seminars in Perinatology·Beryl R Benacerraf
Jan 2, 2007·Obstetrics and Gynecology·UNKNOWN ACOG Committee on Practice Bulletins
Mar 21, 2007·Prenatal Diagnosis·Rebecca Smith-BindmanJames D Goldberg
May 2, 2007·Obstetrics and Gynecology·Boaz WeiszCharles H Rodeck
May 12, 2007·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·D A KrantzJ N Macri
Jan 29, 2009·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·J N BottalicoL Nelson
Jun 12, 2009·The New England Journal of Medicine·Deborah A Driscoll, Susan Gross

❮ Previous
Next ❯

Citations

Nov 4, 2016·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Hua-Pin ChangPen-Hua Su

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Obstetrics and Gynecology Clinics of North America
Karlla W Brigatti, Fergal D Malone
Fetal Diagnosis and Therapy
Erno Tóth-PálZoltán Papp
© 2021 Meta ULC. All rights reserved